Israeli company creates possible cancer vaccine
Published: Monday, November 21, 2011
Updated: Tuesday, November 22, 2011 00:11
TEL AVIV, Israel—Scientists at Vaxil BioTherapeutics Ltd., a clinical-stage company in Israel, are developing an innovative cancer vaccine, according to the company database of the non-profit corporation Israel Life Science Industry. A recent article published on the website of United with Israel, a grassroots organization that focuses on Israel advocacy, reported that the vaccine is now in clinical trials at Hadassah University Medical Center in Jerusalem.
Specifically, the vaccine is being assessed in the presence of multiple myeloma, a blood cancer. If successful, Vaxil's pioneering technology that developed the vaccine, VaxHit, could then be tried against all identified cancers and additionally examine the vaccine's effect on solid and non-solid tumors, according to United with Israel. The article also states that the vaccine, well on its way to success, is projected to be available for public use in six years, and is predicted to prevent about 90 percent of cancer recurrence. Vaxil's research currently focuses on creating novel synthetic T-cell therapeutic and preventative vaccines that act more like drugs than typical vaccines.